SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 14, 2004
| | | |
GUILFORD PHARMACEUTICALS INC.
|
| (Exact name of registrant as specified in its charter) |
| |
| | | | | |
Delaware
| | 0-23736
| | 52-1841960
|
(State or other jurisdiction of
incorporation or organization) | | (Commission File
Number) | | (I.R.S. Employer
Identification No.) |
| |
| | | |
6611 Tributary Street Baltimore, Maryland
| | 21224
|
| (Address of principal executive offices) | | (Zip Code) |
| | | |
| |
Registrant’s telephone number, including area code: (410) 631-6300
| | | |
|
| (Former name or former address, if changed since last report) |
| |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-1-
INFORMATION TO BE INCLUDED IN THE REPORT
Item 8.01. Other Events.
On September 14, 2004, Guilford Pharmaceuticals Inc. issued a press release announcing the receipt of European marketing authorization for the expanded use of GLIADEL® Wafer. A copy of the press release is included as Exhibit 99.1 to this report.
Item 9. Financial Statements and Exhibits.
| 99.1 | | Press release announcing the receipt of European marketing authorization for the expanded use of GLIADEL® Waver dated September 14, 2004. |
| |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | Guilford Pharmaceuticals Inc. |
| | | | | |
| Date: September 14, 2004 | | By: | | /s/ Asher M. Rubin
Asher M. Rubin
Vice President, General Counsel and Secretary |
| |
-3-
